Company Overview of Xencor, Inc.
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company’s lead XmAb-engineered antibodies include XmAb5871, a B-cell inhibitor, which is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases; XmAb7195, an IgE inhibitor that is in Phase Ib clinical trials initiation to treat asthma and allergic diseases; and XmAb5574/MOR208, a Cytotoxic B-cell depleting product candidate, which is in Phase II clinical t...
111 West Lemon Avenue
Monrovia, CA 91016
Founded in 1997
Key Executives for Xencor, Inc.
Co-Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $400.0K
Chief Medical Officer
Total Annual Compensation: $369.0K
Chief Business Officer
Total Annual Compensation: $290.0K
Chief Scientific Officer and Senior Vice President of Research
Total Annual Compensation: $289.3K
Compensation as of Fiscal Year 2014.
Xencor, Inc. Key Developments
Xencor, Inc. - Analyst/Investor Day
Jun 12 15
To provide updates on its XmAb5871 and XmAb7195 development programs and its XmAb14045 and XmAb bispecific pipeline
Xencor Reports Complete Data Results on XmAb5871 Program at European League Against Rheumatism (EULAR) 2015 Annual Meeting
Jun 10 15
Xencor, Inc. reported complete data results from a Phase 1b/2a study of XmAb®5871 in patients with rheumatoid arthritis (RA). XmAb5871 was generally well tolerated and showed trends in improvement in RA disease activity by multiple disease activity measures and across multiple dose groups. The two-part study was designed as a Phase 1b multiple center, randomized, placebo-controlled, double-blinded, multiple ascending dose clinical study (Part A) followed by Phase 2a cohort extension (Part B) at the top dose examined in Part A. The study enrolled patients with active RA on stable non-biologic DMARD therapy. Patients were randomized to receive ascending IV infusions of XmAb5871 (0.3, 1.0, 3.0 and 10.0 mg/kg) or placebo 14 days apart for six doses (Part A), followed by an expansion cohort at 10.0 mg/kg or placebo 14 days apart for six doses (Part B). XmAb5871 was safe and generally well tolerated. The most common AEs in the XmAb5871 group were vomiting, headache and nausea. Nausea and vomiting occurred primarily during the first infusion, were generally of mild to moderate intensity and were self-limiting. Two subjects in the study experienced infusion-related reactions with hypotension (both at 10 mg/kg) and were discontinued. The nature and severity of these infusion reactions were consistent with those reported for other monoclonal antibody therapies. Two SAEs occurred in two XmAb5871 treated patients, both in the 10 mg/kg group: one infusion-related reaction with hypotension occurring during the second infusion, and one deep venous thrombosis with onset 22 days (> 6 half-lives) after the last infusion.
Xencor, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 08:30 AM
May 26 15
Xencor, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 08:30 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Bassil I. Dahiyat, Co-Founder, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|